Citations

Showing 10 of 108119 citations.

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Foltz, Lynda, Ritchie, Ellen K. , Silver, Richard T. , Hong, Wan‐Jen , Kremyanskaya, Marina , Trehu, Elizabeth, Verstovšek, Srđan , Mesa, Ruben A. , Gupta, Vikas , Mascarenhas, John , Hoffman, Ronald , Kantarjian, Hagop M. , Gotlib, Jason

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7114-7114

10.1200/jco.2014.32.15_suppl.7114 Get It

Activity of the Wee1 inhibitor MK1775 plus cytarabine in AML through interference with DNA repair capacity at the DNA level.
Chaudhuri, Leena, Hansen, Nanna, Delman, Devora, Tibes, Raoul , Bogenberger, James M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7106-7106

10.1200/jco.2014.32.15_suppl.7106 Get It

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).
Ritchie, Ellen K. , Sanford, Ben L. , Marcucci, Guido , Zhao, Weiqiang , Geyer, Susan M. , Powell, Bayard L., Baer, Maria R. , Cohen, Harvey Jay, Stone, Richard M. , Klepin, Heidi D. , Ballman, Karla V. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey L.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7102-7102

10.1200/jco.2014.32.15_suppl.7102 Get It

Correlation of KIT expression with higher FLT3 mutations and impact on clinical outcome in patients newly diagnosed with acute myeloid leukemia (AML).
Litzow, Mark R. , Baidoun, Firas , Hashmi, Shahrukh K. , Patnaik, Mrinal M. , Elliott, Michelle A. , Al‐Kali, Aref , Alkhateeb, Hassan B. , Hogan, William J. , Chen, Dong , Baidoun, Firas

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7067-7067

10.1200/jco.2014.32.15_suppl.7067 Get It

Evaluation of possible prognostic factors in patients with acute myeloid leukemia (univariate and multivariate analysis).
Al-Ameri, Ali , Nayfe, Rabih , Kanaan, Zeyade, Al‐Kali, Aref , Abdelfatah, Mohamed M. , Elkhanany, Ahmed , Kanaan, Zeyad

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e18015-e18015

10.1200/jco.2014.32.15_suppl.e18015 Get It

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Durrant, S. T. S., Harrison, Claire , He, Shui, Garrett, William M., Li, Jingjin , Pirron, Ulrich, Lawniczek, Tomasz, Verstovšek, Srđan , Kiladjian, Jean‐Jacques , Grießhammer, Martin , Masszi, Tamás , Passamonti, Francesco , Pane, Fabrizio , Zachée, Pierre , Mesa, Ruben A. , Jones, Mark, Vannucchi, Alessandro M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7026-7026

10.1200/jco.2014.32.15_suppl.7026 Get It

Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).
Litzow, Mark R. , Morris, Lawrence E. , Levy, Moshe , Gojo, Ivana , Gocke, Christopher D. , Rosner, Gary L. , Greer, Jacqueline M., Cain, Joan McFadden, Little, Richard F. , Wright, John Joseph, Doyle, L. Austin, Karp, Judith E. , Zeidner, Joshua F. , Foster, Matthew C , Blackford, Amanda , Strickland, Stephen Anthony , Lancet, Jeffrey E. , Bose, Prithviraj , Tibes, Raoul , Smith, B. Douglas

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7002-7002

10.1200/jco.2014.32.15_suppl.7002 Get It

Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy.
Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Marks, Randolph S., Grothey, Axel , Sargent, Daniel J. , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6630-6630

10.1200/jco.2014.32.15_suppl.6630 Get It

Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase III (P3) overall survival (OS) outcomes using the RECIST 1.1 database.
Mandrekar, Sumithra J. , An, Ming‐Wen , Han, Yu , Group, RECIST Working, Sargent, Daniel J. , Group, RECIST Working

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 6600-6600

10.1200/jco.2014.32.15_suppl.6600 Get It

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.
Satele, Daniel , Puttabasavaiah, Suneetha, Buckner, Jan C. , Sloan, Jeff A. , Singh, Jasvinder A. , Locke, Dona E.C.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e17619-e17619

10.1200/jco.2014.32.15_suppl.e17619 Get It